Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 121 | 29 | 91 |
| Samples | 120 | 29 | 90 |
| Peptides | 96 | 19 | 76 |
Function
CCNO · Cyclin O
This gene encodes a member of the cyclin protein family, and the encoded protein is involved in regulation of the cell cycle. Disruption of this gene is associated with primary ciliary dyskinesia-19. Alternative splicing results in multiple transcript variants. This gene, which has a previous symbol of UNG2, was erroneously identified as a uracil DNA glycosylase in PubMed ID: 2001396. A later publication, PubMed ID: 8419333, identified this gene's product as a cyclin protein family member. The UNG2 symbol is also used as a specific protein isoform name for the UNG gene (GeneID 7374), so confusion exists in the scientific literature and in some databases for these two genes. [provided by RefSeq, Jul 2014].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000282572 | P22674 | 121 | 96 |
Gene Properties
Recurrent Mutations
All 96 amino-acid changes on canonical ENST00000282572 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CCNO · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CCNO – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Endometrial Carcinoma | 1/42 2% | 6/612 1% |
| Non-Cancerous | 2/104 2% | 4/830 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 8/1592 0% |
| Hepatocellular Carcinoma | 1/46 2% | 10/2210 0% |
| Gastric Carcinoma | 1/74 1% | 8/1809 0% |
| Ovarian Carcinoma | 2/109 2% | 3/998 0% |
| Melanoma | 2/210 1% | 7/1899 0% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 6/1390 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 8/2550 0% |
| Other Solid Cancers | 1/94 1% | 5/1515 0% |
| Colorectal Carcinoma | 3/143 2% | 8/3239 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Neuroendocrine Tumour | 1/154 1% | 1/577 0% |
| Small Cell Lung Carcinoma | 1/9 11% | 1/752 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 1/810 0% |
| Pancreatic Carcinoma | 1/89 1% | 1/1611 0% |
| B-Cell Non-Hodgkins Lymphoma | 1/88 1% | 2/2534 0% |
| Other Blood Cancers | 0/61 0% | 3/2725 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Breast Carcinoma | 1/144 1% | 2/3264 0% |
| Head and Neck Carcinoma | 1/85 1% | 0/1574 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 0/2640 0% |
Mutation Distribution
Where CCNO is mutated · all tissues, split by cell line vs tissue
How many mutations in CCNO were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 53 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 121 mutations in CCNO
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|